Pancreatic cancer cells secrete signal that sabotages immune attack on tumours

Pinterest LinkedIn Tumblr +

A key immune signal has a previously unknown role in turning off the immune system’s attack on pancreatic cancer cells, a new study finds.

Led by researchers at NYU Grossman School of Medicine, USA, the study found that an immune signalling protein, interleukin-1β (IL-1β), is made and released by pancreatic tumour cells.

This was shown to reduce anti-cancer immune responses, which promoted the growth of pancreatic ductal adenocarcinoma or PDA, a form of cancer that is usually deadly within two years.

Published online in Cancer Research, a journal of the American Association for Cancer Research, on January 8, the study found that blocking the action of IL-1β in mice with immune proteins called antibodies caused a 32 percent decrease in PDA tumour growth.

Other experiments combined the anti-IL-1β antibody, which gloms onto and neutralises its target, with an already approved antibody treatment that shuts down the protein “checkpoint” called PD1.

To spare normal cells from immune attack, the immune system uses “checkpoints” on immune cells that turn them off when they receive the right signal.

Cancer cells hijack checkpoints to turn off the system, leading to immune suppression of CD8 T cells that would otherwise kill cancer cells.

Therapies called checkpoint inhibitors counter this effect.

While effective against many cancers, checkpoint inhibitors have failed in PDA, with the response rate in tumours as low as roughly three percent in some trials, and the limitations attributed to poor CD8 T cell infiltration and immune suppression.

In the current study, adding anti-IL-1β antibodies to anti-PD-1 antibody treatment doubled the infiltration of such T cells into PDA tumours and increased the anti-tumour activity of PD-1 blockade by 40 percent.

“By engineering mice with versions of PDA that lack the IL-1β gene, we found for the first time that pancreatic cancer cells produce IL-1β, and that it is essential for the continued growth of PDA tumours,” says study senior author Dafna Bar-Sagi, PhD, Vice Dean for Science and Chief Science Officer for NYU Langone Health.

“Blocking IL-1β with an antibody treatment may represent another way to make pancreatic tumours vulnerable to the immune system, with the potential to significantly increase the effectiveness of checkpoint inhibitors if combined.”

The new finding is in line with past work in other labs that had described the microbiome, the mix of bacterial species in the pancreas, as being altered in the presence of PDA, and a factor in cancer growth.

The field had traditionally assigned the production of IL-1β to immune cells, but the new work finds that pancreatic tumour cells can also make it in response to proteins given off by certain bacteria.

Bacterial products were found to activate proteins on the cancer cell surfaces called toll-like receptors, which set off chain reactions that were required for IL-1β production in cancer cells.

The research team also found that higher IL-1β production caused nearby pancreatic stellate cells to increase production of dense, structural proteins like collagen.

Desmoplasia is the overgrowth of such fibrous tissue that often occurs near pancreatic tumours, and which has been linked to treatment resistance.

Active stellate cells were also found to trigger production of the signalling proteins that attract immune cells called macrophages into tumours and programs them to become the type (M2) that suppresses immune reactions. Experiments also confirmed that higher IL-1β and M2 macrophage levels, along with fibroblast-driven desmoplasia, reduced the ability of cancer-cell-killing CD8 T cells to enter tumours.

“This work provides strong evidence that blocking the action of IL-1β enables T cells to better penetrate tumours and kill cancer cells, mechanisms with potential to overcome the limitation of currently available immunotherapies in the treatment of pancreatic cancer,” says first author Shipra Das, who was a member of Bar-Sagi’s lab at the time the study was done.

Source: NYU Langone Health / NYU School of Medicine


About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.